JP2007532527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532527A5 JP2007532527A5 JP2007506899A JP2007506899A JP2007532527A5 JP 2007532527 A5 JP2007532527 A5 JP 2007532527A5 JP 2007506899 A JP2007506899 A JP 2007506899A JP 2007506899 A JP2007506899 A JP 2007506899A JP 2007532527 A5 JP2007532527 A5 JP 2007532527A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- standardized
- tinospora cordifolia
- cordifolia extract
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000003428 Tinospora crispa Species 0.000 claims 8
- 208000017169 kidney disease Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 208000019206 urinary tract infection Diseases 0.000 claims 5
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- -1 amoxiline Chemical compound 0.000 claims 2
- 238000004166 bioassay Methods 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 238000011443 conventional therapy Methods 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims 1
- 206010061259 Klebsiella infection Diseases 0.000 claims 1
- 208000024233 Klebsiella infectious disease Diseases 0.000 claims 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 238000011203 antimicrobial therapy Methods 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229940047766 co-trimoxazole Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001571 immunoadjuvant effect Effects 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229960002422 lomefloxacin Drugs 0.000 claims 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960000564 nitrofurantoin Drugs 0.000 claims 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims 1
- 229960001180 norfloxacin Drugs 0.000 claims 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims 1
- 229960001699 ofloxacin Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56133504P | 2004-04-09 | 2004-04-09 | |
| US60/561,335 | 2004-04-09 | ||
| PCT/IB2005/051103 WO2005097149A2 (en) | 2004-04-09 | 2005-04-04 | Herbal extract for renal disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007532527A JP2007532527A (ja) | 2007-11-15 |
| JP2007532527A5 true JP2007532527A5 (https=) | 2008-05-15 |
| JP5117183B2 JP5117183B2 (ja) | 2013-01-09 |
Family
ID=35125612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506899A Expired - Fee Related JP5117183B2 (ja) | 2004-04-09 | 2005-04-04 | 腎障害のための薬草抽出物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7914824B2 (https=) |
| EP (1) | EP1732579B1 (https=) |
| JP (1) | JP5117183B2 (https=) |
| CN (1) | CN1921874B (https=) |
| AU (1) | AU2005230727B2 (https=) |
| CA (1) | CA2555356C (https=) |
| ES (1) | ES2431522T3 (https=) |
| WO (1) | WO2005097149A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007093897A2 (en) * | 2006-02-16 | 2007-08-23 | Promed Exports Private Limited | Process of making herbal composition with masked bitter taste and product thereof |
| JP2013043861A (ja) * | 2011-08-24 | 2013-03-04 | Japan Enviro Chemicals Ltd | 尿臭抑制剤 |
| WO2018198134A2 (en) * | 2017-04-24 | 2018-11-01 | Muniyal Ayurvedic Research Centre | Herbo-mineral formulation for prevention, treatment and management of renal disorders and method of preparation thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991008750A1 (de) | 1989-12-19 | 1991-06-27 | Krueger Christian | Verwendung von pflanzenteilen der naturpflanze tinospora |
| US6075024A (en) * | 1991-11-27 | 2000-06-13 | Sepracor Inc. | Methods for treating infection using optically pure (S)-lomefloxacin |
| US5486160A (en) * | 1994-05-04 | 1996-01-23 | Physion S.R.L. | Device and method for the combined electropharmacological treatment of the bladder and the prostatic urethra |
| US5529778A (en) * | 1994-09-13 | 1996-06-25 | Rohatgi; Surendra | Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same |
| US6136316A (en) * | 1996-04-17 | 2000-10-24 | Dabur Research Foundation | Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection |
| US5886029A (en) * | 1997-09-05 | 1999-03-23 | Dhaliwal; Kirpal S. | Method and composition for treatment of diabetes |
| IN183805B (https=) | 1998-01-29 | 2000-04-22 | Bhabha Atomic Res Ct | |
| IN191359B (https=) * | 1999-04-20 | 2003-11-29 | Nat Inst Immunology | |
| US6428785B1 (en) * | 1999-10-28 | 2002-08-06 | Immunolytics Inc. | Method and composition for treating prostate cancer |
| EP1345615A1 (en) * | 2000-12-28 | 2003-09-24 | Noel John De Souza | Use of tinospora extract in the treatment of immune system-modulated disorders |
| GB0116942D0 (en) * | 2001-07-11 | 2001-09-05 | Sahajanand Biotech Private Ltd | Herbal formulation |
-
2005
- 2005-04-04 WO PCT/IB2005/051103 patent/WO2005097149A2/en not_active Ceased
- 2005-04-04 ES ES05718625T patent/ES2431522T3/es not_active Expired - Lifetime
- 2005-04-04 CN CN2005800051905A patent/CN1921874B/zh not_active Expired - Fee Related
- 2005-04-04 JP JP2007506899A patent/JP5117183B2/ja not_active Expired - Fee Related
- 2005-04-04 AU AU2005230727A patent/AU2005230727B2/en not_active Ceased
- 2005-04-04 CA CA2555356A patent/CA2555356C/en not_active Expired - Lifetime
- 2005-04-04 EP EP05718625.6A patent/EP1732579B1/en not_active Expired - Lifetime
- 2005-04-04 US US10/591,023 patent/US7914824B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6099609B2 (ja) | 肺炎症を低減するためのレボフロキサシンの吸入 | |
| CN105263579B (zh) | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 | |
| EP2799071A1 (en) | Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation | |
| JP2018507914A5 (https=) | ||
| JP2013521303A5 (https=) | ||
| JP2015527364A5 (https=) | ||
| US20180185404A1 (en) | Compositions and methods for the treatment of viral infection | |
| JP6313413B2 (ja) | アナフィラキシーの処置におけるレボセチリジン及びモンテルカストの使用 | |
| JP2020522560A5 (https=) | ||
| JP2023500032A5 (https=) | ||
| RU2007107915A (ru) | Лекарственные средства для лечения хронического респираторного заболевания | |
| JP2016505561A5 (https=) | ||
| JP2019507786A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| An et al. | Anti-asthma and antitussive effects of a fermented extract of a mixture of Ramulus mori, Anthriscus sylvestris, and Salvia plebeian | |
| JP2007532527A5 (https=) | ||
| CN111419800A (zh) | 用于治疗红斑狼疮的药物制剂及其制备方法 | |
| JP2008533079A5 (https=) | ||
| CN101057840B (zh) | Vam3在制备治疗慢性阻塞性肺疾病的药物中的应用 | |
| KR101215709B1 (ko) | 난백알부민을 유효성분으로 포함하는 알레르기 질환 예방 또는 치료용 조성물 | |
| Wagenlehner et al. | Safety and efficacy of finafloxacin versus ciprofloxacin in the treatment of hospitalized patients with complicated urinary tract infections and pyelonephritis determined in a phase 2 clinical study | |
| JP2007506768A5 (https=) | ||
| JPWO2005063253A1 (ja) | アレルギー症状治療用医薬組成物 | |
| JP2009007332A (ja) | アゼラスチン類とエフェドリン類を含有する医薬組成物 | |
| JP2024515385A (ja) | トリシクロ誘導体化合物を含む代謝性疾患の予防または治療用組成物 |